目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB...目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB1表达对肺腺癌增殖的影响仍不清楚。本研究探讨了GPRC5A调控的ABCB1表达对肺腺癌增殖的影响。方法我们采用RT-PCR、Western-blot或免疫组化实验,分析ABCB1在肺腺癌细胞系、人肺腺癌组织以及GPRC5A基因敲除小鼠和野生型小鼠的气管上皮细胞和肺组织中的表达。采用细胞计数试剂盒-8(CCK-8)分析GPRC5A基因敲除小鼠气管上皮细胞对化疗药物的敏感性。采用皮下肿瘤形成实验探讨下调ABCB1表达是否可抑制体内肺腺癌增殖。采用免疫荧光和免疫沉淀实验研究GPRC5A和ABCB1之间潜在的调控关系。结果ABCB1在肺腺癌细胞系和人类肺腺癌组织中表达上调。GPRC5A基因敲除小鼠的气管上皮细胞及肺组织的ABCB1表达高于野生型小鼠。与GPRC5A野生型小鼠的气管上皮细胞相比,GPRC5A基因敲除小鼠的气管上皮细胞对塔立奇达和多柔比星更敏感。注射移植细胞28天后,接受ABCB1基因敲除细胞移植的GPRC5A-/-C57BL/6小鼠的肺肿瘤的体积和重量均明显低于野生型细胞移植小鼠(P=0.0043,P=0.0060)。此外,免疫荧光和免疫沉淀实验表明,GPRC5A通过直接结合方式调控ABCB1的表达。结论GPRC5A通过抑制ABCB1表达降低肺腺癌增殖。GPRC5A调节ABCB1表达的途径有待研究。展开更多
AIM To investigate effect of losartan,an AT1receptor antagonist,on hepatic fibrosis induced byCCl<sub>;</sub>and to determine whether or not AT1receptors are expressed on hepatic stellate cells,METHODS AND...AIM To investigate effect of losartan,an AT1receptor antagonist,on hepatic fibrosis induced byCCl<sub>;</sub>and to determine whether or not AT1receptors are expressed on hepatic stellate cells,METHODS AND RESULTS Fifty male Sprague-Dawley rats,weighing（180±20）g,wererandomized into five groups（control group,modelgroup,and three losartan treated groups）,inwhich all rats were given the subcutaneousinjection of 40% CCl<sub>4</sub>（every 3 days for 6 weeks）except for rats of control group.Rats of losartan-treated groups were treated with losartan（20 mg/kg,10 mg/kg,5 mg/kg,daily gavage）,After 6weeks liver tissue and serum samples of all ratswere examined.Serum hyaluronic acid（HA）,procollagen typeⅢ（PCⅢ）were detected byradioimmunoassays,van Giesion collagen stainingwas used to evaluate the extracellular matrix of ratswith liver fibrosis.The expression of AT1receptors,transforming growth factor-beta（TGF-β）,and alpha-smooth muscle actin（a-SMA）inliver tissue were determined byimmunohistochemical techniques.Compared withmodel group,serum ALT and AST of losartan-treated groups were significantly reduced（t=4.20,P【0.01 and t=4.57,P【0.01）.Serum HAand PCⅢalso had significant differences（t=3.53,P【0.01 and t=2.20,P【0.05）.Thedegree of fibrosis was improved by losartan and correlated with the expressions of AT1 receptors,TGF-β,and α-SMA in liver tissue.CONCLUSION AT1 receptor antagonist,losartan,could limit the progression of the hepatic fibrosisinduced by CCl<sub>4</sub>.The mechanism may be related tothe decrease in the expression of AT1 receptorsand TGF-β,ameliorating the injury of hepatocytes;activation of local renin-angiotensin system mightrelate to hepatic fibrosis;and during progressionof fibrosis,activated hepatic stellate cells mightexpress AT1 receptors.展开更多
AIM: To investigate the roles of nuclear factor(NF)-κB and angiotensin Ⅱ receptor type 1(AT1R) in the pathogenesis of non-alcoholic fatty liver disease(NAFLD).METHODS: Forty-two healthy adult male SpragueDawley rats...AIM: To investigate the roles of nuclear factor(NF)-κB and angiotensin Ⅱ receptor type 1(AT1R) in the pathogenesis of non-alcoholic fatty liver disease(NAFLD).METHODS: Forty-two healthy adult male SpragueDawley rats were randomly divided into three groups:the control group(normal diet), the model group,and the intervention group(10 wk of a high-fat diet feeding, followed by an intraperitoneal injection of PDTC); 6 rats in each group were sacrificed at 6, 10,and 14 wk. After sacrifice, liver tissue was taken,paraffin sections of liver tissue specimens were prepared, hematoxylin and eosin(HE) staining was performed, and pathological changes in liver tissue(i.e., liver fibrosis) were observed by light microscopy.NF-κB expression in liver tissue was detected by immunohistochemistry, and the expression of AT1 R in the liver tissue was detected by reverse transcriptionpolymerase chain reaction(RT-PCR). The data are expressed as mean ± SD. A two-sample t test was used to compare the control group and the model group at different time points, paired t tests were used to compare the differences between the intervention group and the model group, and analysis of variance was used to compare the model group with the control group. Homogeneity of variance was analyzed with single factor analysis of variance. H variance analysis was used to compare the variance. P < 0.05 wasconsidered statistically significant.RESULTS: The NAFLD model was successful after 6wk and 10 wk. Liver fibrosis was found in four rats in the model group, but in only one rat in the intervention group at 14 wk. Liver steatosis, inflammation, and fibrosis were gradually increased throughout the model. In the intervention group, the body mass,rat liver index, serum lipid, and transaminase levels were not increased compared to the model group.In the model group, the degree of liver steatosis was increased at 6, 10, and 14 wk, and was significantly higher than in the control group(P < 0.01). In the model group, different degrees of liver cell necrosis were visible and small leaves, punctated inflammation,focal necrosis, and obvious ballooning degeneration were observed. Partial necrosis and confluent necrosis were observed. In the model group, liver inflammatory activity scores at 6, 10, and 14 wk were higher than in the control group(P < 0.01). Active inflammation in liver tissue in the intervention group was lower than in the model group(P < 0.05). HE staining showed liver fibrosis only at 14 wk in 4/6 rats in the model group and in 1/6 rats in the intervention group. NF-κB positive cells were stained yellow or ensemble yellow,and NF-κB was localized in the cytoplasm and/or nucleus. The model group showed NF-κB activation at6, 10, and 14 wk in liver cells; at the same time points,there were statistically significant differences in the control group(P < 0.01). Over time, NF-κB expression increased; this was statistically lower(P < 0.05) at14 weeks in the intervention group compared to the model group, but significantly increased(P < 0.05)compared with the control group; RT-PCR showed that AT1 R mRNA expression increased gradually in the model group; at 14 wk, the expression was significantly different compared with expression at 10 weeks as well as at 6 weeks(P < 0.05). In the model group, AT1 R mRNA expression was significantly higher than at the same time point in the control group(P <0.01).CONCLUSION: With increasing severity of NAFLD,NF-κB activity is enhanced, and the inhibition of NF-κB activity may reduce AT1 R mRNA expression in NAFLD.展开更多
Objective To study the effect of Asparagus officinalis polysaccharide on the number and activity of erythrocyte complement receptor 1 in S180 mice.Methods Red blood cells from mice venous blood were labeled by rat ant...Objective To study the effect of Asparagus officinalis polysaccharide on the number and activity of erythrocyte complement receptor 1 in S180 mice.Methods Red blood cells from mice venous blood were labeled by rat anti-mouse CD35 monoclonal antibody and FITC-conjugated goat anti-mouse antibody.Using flow cytometry,we determined the number of ECR1.Using microscope,we studied the adherence between erythrocyte immunity and C3b receptor or tumor-cell by RBC-C3bRR and DTER.Results Comparing the mean value of the number of CR1 on each RBC of high and middle groups with control groups,the mean value of the number of CR1,RBC-C3bRR and DTER of Asparagus officinalis polysaccharide groups are increased significantly.Conclusions Asparagus officinalis polysaccharide can improve the erythrocyte function of S180 mice,which may be one of its most important antitumor mechanisms.展开更多
B类1型清道夫受体(scavenger receptor class Btype1,SR-B1)是一种与清道夫受体CD36具有高度同源性的膜糖蛋白,其表达相对广泛且有着众多生物学作用.体内外多种因素可从转录或转录后水平对SR-B1表达进行调控:PPARα/γ激动剂、部分LXR...B类1型清道夫受体(scavenger receptor class Btype1,SR-B1)是一种与清道夫受体CD36具有高度同源性的膜糖蛋白,其表达相对广泛且有着众多生物学作用.体内外多种因素可从转录或转录后水平对SR-B1表达进行调控:PPARα/γ激动剂、部分LXR激动剂、LH/HCG、雌激素等能上调SR-B1的表达;维生素E、INFα、脂多糖、IGF-1、胆酸、PXR激动剂及高糖水平等能下调SR-B1的表达;而血管紧张素Ⅱ则可对SR-B1的表达进行双向调节,且它们具体的调节机制复杂.SR-B1作为一种具有多配体结合特性的膜受体,不同配体与其结合后可介导细胞内不同信号事件及生物学效应,如介导HDL激活细胞内PI3K/Akt及MAPK信号途径,增加内皮型一氧化氮合酶的磷酸化、促进内皮细胞迁移与内皮重构.此外,非HDL类配体如LDL激活p38MAPK途径、凋亡细胞、血清淀粉样蛋白A等激活胞内MAPK途径均可由SR-B1介导.本文对近年来B类1型清道夫受体表达调控机制及信号转导通路的相关研究进行综述.展开更多
目的 :研究成石饲料对小鼠肝脏脂质代谢相关基因表达的影响,以及PDZK1(PDZ domain-containing 1)的表达对B族Ⅰ型清道夫受体(scavenger receptor B type 1,SRB1)的调节作用。方法:以成石饲料喂养C57BL/6J雄性小鼠,观察肝脏基因表达的影...目的 :研究成石饲料对小鼠肝脏脂质代谢相关基因表达的影响,以及PDZK1(PDZ domain-containing 1)的表达对B族Ⅰ型清道夫受体(scavenger receptor B type 1,SRB1)的调节作用。方法:以成石饲料喂养C57BL/6J雄性小鼠,观察肝脏基因表达的影响。分别构建小鼠PDZK1基因过表达慢病毒载体和Si RNA干扰腺病毒载体,并以成石饲料喂养C57BL/6J小鼠。分别采用实时定量PCR检测小鼠肝脏脂质代谢相关基因的m RNA表达,Western印迹法检测肝脏PDZK1及SRB1的蛋白质表达。结果:成石饲料喂养4周后,小鼠肝脏胆固醇合成关键酶3-羟基-3甲基戊二酰辅酶A还原酶基因表达显著增加(P<0.01)、胆汁酸合成关键酶胆固醇7α-羟化酶基因表达显著下降(P<0.001);PDZK1基因的表达显著抑制,SRB1基因表达相应降低(P<0.001)。PDZK1过表达慢病毒载体经腹腔注射成石饲料喂养的小鼠,4周后肝脏PDZK1蛋白表达增加37%(P<0.01),SRB1在总蛋白的表达量未改变,但在膜蛋白中表达增加136%(P<0.05)。将PDZK1的Si RNA腺病毒载体经腹腔注射成石饲料喂养的小鼠,2周后肝脏PDZK1蛋白的表达量降低49%(P<0.05),SRB1在总蛋白中表达增加60%(P<0.05),但在膜蛋白中的表达则下降14%。结论:成石饲料影响小鼠肝脏脂质代谢相关基因的表达。SRB1表达降低可能与PDZK1的抑制有关。干预小鼠肝脏PDZK1的表达会影响SRB1在肝细胞膜上的表达。展开更多
目的:观察姜黄素对β-淀粉样前体蛋白swe基因/早老蛋白1dE9基因(APPswe/PSEN1dE9)双转基因小鼠海马神经元B类Ⅰ型清道夫受体(scavenger receptor class B typeⅠ,SR-BⅠ)和三磷酸腺苷结合盒A1(ATP-binding cassette transporter,ABCA1)...目的:观察姜黄素对β-淀粉样前体蛋白swe基因/早老蛋白1dE9基因(APPswe/PSEN1dE9)双转基因小鼠海马神经元B类Ⅰ型清道夫受体(scavenger receptor class B typeⅠ,SR-BⅠ)和三磷酸腺苷结合盒A1(ATP-binding cassette transporter,ABCA1)表达的影响,探讨姜黄素在阿尔茨海默病(Alzheimer’s disease,AD)防治中的机制。方法:将10只6月龄的APPswe/PSEN1dE9双转基因小鼠随机分为对照组和姜黄素饲喂组,每组5只。姜黄素饲喂组每天饲喂500 ppm姜黄素,6个月后采用免疫组化法检测小鼠海马神经元SR-BⅠ和ABCA1表达的变化。结果:与对照组相比,姜黄素饲喂组小鼠海马神经元ABCA1表达明显增加(t=-10.805,P=0.000),但2组小鼠海马神经元中均未见SR-BⅠ表达。结论:姜黄素能提高APPswe/PSEN1dE9双转基因小鼠海马神经元ABCA1的表达,而SR-BⅠ在神经元中未见表达。展开更多
目的研究胃癌患者癌组织中长链非编码RNA(long non-coding RNA,lncRNA)FOXC2-AS1及清道夫受体B组1型分子(scavenger receptor class B typeⅠ,SCARB1)的表达及其临床意义。方法选择2016年5月至2017年9月湖南省郴州市第一人民医院收治的9...目的研究胃癌患者癌组织中长链非编码RNA(long non-coding RNA,lncRNA)FOXC2-AS1及清道夫受体B组1型分子(scavenger receptor class B typeⅠ,SCARB1)的表达及其临床意义。方法选择2016年5月至2017年9月湖南省郴州市第一人民医院收治的96例胃癌患者,采用实时荧光定量PCR检测癌组织中FOXC2-AS1和SCARB1的表达,以癌旁正常组织为对照,分析癌组织中FOXC2-AS1、SCARB1表达与临床病理特征的关系,Pearson法分析FOXC2-AS1与SCARB1的相关性。Kaplan-Meier法(Log-rank检验)分析不同FOXC2-AS1、SCARB1表达水平患者的预后差异。结果与癌旁正常组织相比,癌组织中FOXC2-AS1表达水平明显较高,SCARB1表达水平明显较低。不同肿瘤分期、病理分级癌组织中FOXC2-AS1、SCARB1的表达差异具有显著性(P<0.05)。癌组织中FOXC2-AS1和SCARB1的表达呈显著负相关(r=-0.663,P=0.000)。高FOXC2-AS1表达组患者3年总体生存率明显低于低FOXC2-AS1表达组患者,低SCARB1表达组患者3年总体生存率明显低于高SCARB1表达组患者(P<0.05)。结论胃癌组织中FOXC2-AS1表达升高,SCARB1表达降低,二者均与肿瘤TNM分期、病理分级有关,可作为判断胃癌预后的肿瘤标志物。展开更多
BACKGROUND:Non-alcoholic fatty liver disease(NAFLD)is one of the most frequent causes of liver diseases,with markedly increased prevalence.However,its mechanisms are not clear.The present study was undertaken to illus...BACKGROUND:Non-alcoholic fatty liver disease(NAFLD)is one of the most frequent causes of liver diseases,with markedly increased prevalence.However,its mechanisms are not clear.The present study was undertaken to illustrate the role of caveolin-1(cav1)and the scavenger receptor class B type 1(SR-B1)in NAFLD.METHODS:Adult male C57BL/6 mice were fed with a normal diet or high fat and cholesterol(HFC)diet for 14 weeks.The mice were sacrificed to collect plasma and harvest the liver;their plasma lipid concentration was measured.Hepatic cav1and SR-B1 mRNA and protein expression were determined by real-time quantitative polymerase chain reaction(qPCR)and Western blotting,respectively.In order to study cav1 and SR-B1distribution and change in hepatocytes,immunohistochemical analysis was performed.RESULTS:HFC diet increased plasma lipids,induced NAFLD and increased the liver/body weight ratio.Compared to the control mice(n=6),the mRNA and protein levels of cav1 and SR-B1 in liver tissue of the NAFLD mice(n=12)increased significantly(cav1 mRNA:1.536±0.226 vs 0.980±0.272,P【0.05;protein:0.643±0.240 vs 0.100±0.130,P【0.01;SR-B1 mRNA:1.377±0.125 vs 0.956±0.151,P【0.01;protein:2.156±0.507vs 0.211±0.211,P【0.01).Furthermore,both cav1 and SR-B1immunoreactivity increased and their distribution was also changed,mainly in the plasma membrane of hepatocytes,cytoplasm and membrane of lipid droplets and around.CONCLUSION:NAFLD is associated with increased concentration of plasma lipids and upregulation of hepatic cav1 and SR-B1 gene and protein expressions,which indicate that cav1 and SR-B1 might play crucial roles in the pathogenesis of NAFLD.展开更多
Type 2 diabetes mellitus is a metabolic disorder of deranged fat, protein and carbohydrate metabolism resulting in hyperglycemia as a result of insulin resistance and inadequate insulin secretion. Although a wide vari...Type 2 diabetes mellitus is a metabolic disorder of deranged fat, protein and carbohydrate metabolism resulting in hyperglycemia as a result of insulin resistance and inadequate insulin secretion. Although a wide variety of diabetes therapies is available, yet limited efficacy, adverse effects, cost, contraindications, renal dosage adjustments, inflexible dosing schedules and weight gain significantly limit their use. In addition, many patients in the United States fail to meet the therapeutic HbA1c goal of < 7% set by the American Diabetes Association. As such new and emerging diabetes therapies with different mechanisms of action hope to address some of these drawbacks to improve the patient with type 2 diabetes. This article reviews new and emerging classes, including the sodium-glucosecotransporter-2 inhibitors, 11β-Hydroxysteroid dehydrogenase type 1 inhibitors, glycogen phosphorylase inhibitors; protein tyrosine phosphatase 1B inhibitors, G Protein-Coupled receptor agonists and glucokinase activators. These emerging diabetes agents hold the promise of providing benefit of glucose lowering, weight reduction, low hypoglycemia risk, improve insulin sensitivity, pancreatic β cell preservation, and oral formulation availability. However, further studies are needed to evaluate their safety profile, cardiovascular effects, and efficacy durability in order to determine their role in type 2 diabetes management.展开更多
文摘目的ATP结合盒B亚家族成员1(ATP binding cassette subfamily B member 1,ABCB1)的异常表达在多种癌症的发生发展中发挥关键作用。然而,G蛋白偶联受体C家族5组A型(G protein coupled receptor family C group5 type A,GPRC5A)调控的ABCB1表达对肺腺癌增殖的影响仍不清楚。本研究探讨了GPRC5A调控的ABCB1表达对肺腺癌增殖的影响。方法我们采用RT-PCR、Western-blot或免疫组化实验,分析ABCB1在肺腺癌细胞系、人肺腺癌组织以及GPRC5A基因敲除小鼠和野生型小鼠的气管上皮细胞和肺组织中的表达。采用细胞计数试剂盒-8(CCK-8)分析GPRC5A基因敲除小鼠气管上皮细胞对化疗药物的敏感性。采用皮下肿瘤形成实验探讨下调ABCB1表达是否可抑制体内肺腺癌增殖。采用免疫荧光和免疫沉淀实验研究GPRC5A和ABCB1之间潜在的调控关系。结果ABCB1在肺腺癌细胞系和人类肺腺癌组织中表达上调。GPRC5A基因敲除小鼠的气管上皮细胞及肺组织的ABCB1表达高于野生型小鼠。与GPRC5A野生型小鼠的气管上皮细胞相比,GPRC5A基因敲除小鼠的气管上皮细胞对塔立奇达和多柔比星更敏感。注射移植细胞28天后,接受ABCB1基因敲除细胞移植的GPRC5A-/-C57BL/6小鼠的肺肿瘤的体积和重量均明显低于野生型细胞移植小鼠(P=0.0043,P=0.0060)。此外,免疫荧光和免疫沉淀实验表明,GPRC5A通过直接结合方式调控ABCB1的表达。结论GPRC5A通过抑制ABCB1表达降低肺腺癌增殖。GPRC5A调节ABCB1表达的途径有待研究。
文摘AIM To investigate effect of losartan,an AT1receptor antagonist,on hepatic fibrosis induced byCCl<sub>;</sub>and to determine whether or not AT1receptors are expressed on hepatic stellate cells,METHODS AND RESULTS Fifty male Sprague-Dawley rats,weighing（180±20）g,wererandomized into five groups（control group,modelgroup,and three losartan treated groups）,inwhich all rats were given the subcutaneousinjection of 40% CCl<sub>4</sub>（every 3 days for 6 weeks）except for rats of control group.Rats of losartan-treated groups were treated with losartan（20 mg/kg,10 mg/kg,5 mg/kg,daily gavage）,After 6weeks liver tissue and serum samples of all ratswere examined.Serum hyaluronic acid（HA）,procollagen typeⅢ（PCⅢ）were detected byradioimmunoassays,van Giesion collagen stainingwas used to evaluate the extracellular matrix of ratswith liver fibrosis.The expression of AT1receptors,transforming growth factor-beta（TGF-β）,and alpha-smooth muscle actin（a-SMA）inliver tissue were determined byimmunohistochemical techniques.Compared withmodel group,serum ALT and AST of losartan-treated groups were significantly reduced（t=4.20,P【0.01 and t=4.57,P【0.01）.Serum HAand PCⅢalso had significant differences（t=3.53,P【0.01 and t=2.20,P【0.05）.Thedegree of fibrosis was improved by losartan and correlated with the expressions of AT1 receptors,TGF-β,and α-SMA in liver tissue.CONCLUSION AT1 receptor antagonist,losartan,could limit the progression of the hepatic fibrosisinduced by CCl<sub>4</sub>.The mechanism may be related tothe decrease in the expression of AT1 receptorsand TGF-β,ameliorating the injury of hepatocytes;activation of local renin-angiotensin system mightrelate to hepatic fibrosis;and during progressionof fibrosis,activated hepatic stellate cells mightexpress AT1 receptors.
基金Supported by grants from the Science and Technology Department of Sichuan Province,No.2011SZ0094
文摘AIM: To investigate the roles of nuclear factor(NF)-κB and angiotensin Ⅱ receptor type 1(AT1R) in the pathogenesis of non-alcoholic fatty liver disease(NAFLD).METHODS: Forty-two healthy adult male SpragueDawley rats were randomly divided into three groups:the control group(normal diet), the model group,and the intervention group(10 wk of a high-fat diet feeding, followed by an intraperitoneal injection of PDTC); 6 rats in each group were sacrificed at 6, 10,and 14 wk. After sacrifice, liver tissue was taken,paraffin sections of liver tissue specimens were prepared, hematoxylin and eosin(HE) staining was performed, and pathological changes in liver tissue(i.e., liver fibrosis) were observed by light microscopy.NF-κB expression in liver tissue was detected by immunohistochemistry, and the expression of AT1 R in the liver tissue was detected by reverse transcriptionpolymerase chain reaction(RT-PCR). The data are expressed as mean ± SD. A two-sample t test was used to compare the control group and the model group at different time points, paired t tests were used to compare the differences between the intervention group and the model group, and analysis of variance was used to compare the model group with the control group. Homogeneity of variance was analyzed with single factor analysis of variance. H variance analysis was used to compare the variance. P < 0.05 wasconsidered statistically significant.RESULTS: The NAFLD model was successful after 6wk and 10 wk. Liver fibrosis was found in four rats in the model group, but in only one rat in the intervention group at 14 wk. Liver steatosis, inflammation, and fibrosis were gradually increased throughout the model. In the intervention group, the body mass,rat liver index, serum lipid, and transaminase levels were not increased compared to the model group.In the model group, the degree of liver steatosis was increased at 6, 10, and 14 wk, and was significantly higher than in the control group(P < 0.01). In the model group, different degrees of liver cell necrosis were visible and small leaves, punctated inflammation,focal necrosis, and obvious ballooning degeneration were observed. Partial necrosis and confluent necrosis were observed. In the model group, liver inflammatory activity scores at 6, 10, and 14 wk were higher than in the control group(P < 0.01). Active inflammation in liver tissue in the intervention group was lower than in the model group(P < 0.05). HE staining showed liver fibrosis only at 14 wk in 4/6 rats in the model group and in 1/6 rats in the intervention group. NF-κB positive cells were stained yellow or ensemble yellow,and NF-κB was localized in the cytoplasm and/or nucleus. The model group showed NF-κB activation at6, 10, and 14 wk in liver cells; at the same time points,there were statistically significant differences in the control group(P < 0.01). Over time, NF-κB expression increased; this was statistically lower(P < 0.05) at14 weeks in the intervention group compared to the model group, but significantly increased(P < 0.05)compared with the control group; RT-PCR showed that AT1 R mRNA expression increased gradually in the model group; at 14 wk, the expression was significantly different compared with expression at 10 weeks as well as at 6 weeks(P < 0.05). In the model group, AT1 R mRNA expression was significantly higher than at the same time point in the control group(P <0.01).CONCLUSION: With increasing severity of NAFLD,NF-κB activity is enhanced, and the inhibition of NF-κB activity may reduce AT1 R mRNA expression in NAFLD.
文摘Objective To study the effect of Asparagus officinalis polysaccharide on the number and activity of erythrocyte complement receptor 1 in S180 mice.Methods Red blood cells from mice venous blood were labeled by rat anti-mouse CD35 monoclonal antibody and FITC-conjugated goat anti-mouse antibody.Using flow cytometry,we determined the number of ECR1.Using microscope,we studied the adherence between erythrocyte immunity and C3b receptor or tumor-cell by RBC-C3bRR and DTER.Results Comparing the mean value of the number of CR1 on each RBC of high and middle groups with control groups,the mean value of the number of CR1,RBC-C3bRR and DTER of Asparagus officinalis polysaccharide groups are increased significantly.Conclusions Asparagus officinalis polysaccharide can improve the erythrocyte function of S180 mice,which may be one of its most important antitumor mechanisms.
文摘B类1型清道夫受体(scavenger receptor class Btype1,SR-B1)是一种与清道夫受体CD36具有高度同源性的膜糖蛋白,其表达相对广泛且有着众多生物学作用.体内外多种因素可从转录或转录后水平对SR-B1表达进行调控:PPARα/γ激动剂、部分LXR激动剂、LH/HCG、雌激素等能上调SR-B1的表达;维生素E、INFα、脂多糖、IGF-1、胆酸、PXR激动剂及高糖水平等能下调SR-B1的表达;而血管紧张素Ⅱ则可对SR-B1的表达进行双向调节,且它们具体的调节机制复杂.SR-B1作为一种具有多配体结合特性的膜受体,不同配体与其结合后可介导细胞内不同信号事件及生物学效应,如介导HDL激活细胞内PI3K/Akt及MAPK信号途径,增加内皮型一氧化氮合酶的磷酸化、促进内皮细胞迁移与内皮重构.此外,非HDL类配体如LDL激活p38MAPK途径、凋亡细胞、血清淀粉样蛋白A等激活胞内MAPK途径均可由SR-B1介导.本文对近年来B类1型清道夫受体表达调控机制及信号转导通路的相关研究进行综述.
文摘目的:观察姜黄素对β-淀粉样前体蛋白swe基因/早老蛋白1dE9基因(APPswe/PSEN1dE9)双转基因小鼠海马神经元B类Ⅰ型清道夫受体(scavenger receptor class B typeⅠ,SR-BⅠ)和三磷酸腺苷结合盒A1(ATP-binding cassette transporter,ABCA1)表达的影响,探讨姜黄素在阿尔茨海默病(Alzheimer’s disease,AD)防治中的机制。方法:将10只6月龄的APPswe/PSEN1dE9双转基因小鼠随机分为对照组和姜黄素饲喂组,每组5只。姜黄素饲喂组每天饲喂500 ppm姜黄素,6个月后采用免疫组化法检测小鼠海马神经元SR-BⅠ和ABCA1表达的变化。结果:与对照组相比,姜黄素饲喂组小鼠海马神经元ABCA1表达明显增加(t=-10.805,P=0.000),但2组小鼠海马神经元中均未见SR-BⅠ表达。结论:姜黄素能提高APPswe/PSEN1dE9双转基因小鼠海马神经元ABCA1的表达,而SR-BⅠ在神经元中未见表达。
文摘目的研究胃癌患者癌组织中长链非编码RNA(long non-coding RNA,lncRNA)FOXC2-AS1及清道夫受体B组1型分子(scavenger receptor class B typeⅠ,SCARB1)的表达及其临床意义。方法选择2016年5月至2017年9月湖南省郴州市第一人民医院收治的96例胃癌患者,采用实时荧光定量PCR检测癌组织中FOXC2-AS1和SCARB1的表达,以癌旁正常组织为对照,分析癌组织中FOXC2-AS1、SCARB1表达与临床病理特征的关系,Pearson法分析FOXC2-AS1与SCARB1的相关性。Kaplan-Meier法(Log-rank检验)分析不同FOXC2-AS1、SCARB1表达水平患者的预后差异。结果与癌旁正常组织相比,癌组织中FOXC2-AS1表达水平明显较高,SCARB1表达水平明显较低。不同肿瘤分期、病理分级癌组织中FOXC2-AS1、SCARB1的表达差异具有显著性(P<0.05)。癌组织中FOXC2-AS1和SCARB1的表达呈显著负相关(r=-0.663,P=0.000)。高FOXC2-AS1表达组患者3年总体生存率明显低于低FOXC2-AS1表达组患者,低SCARB1表达组患者3年总体生存率明显低于高SCARB1表达组患者(P<0.05)。结论胃癌组织中FOXC2-AS1表达升高,SCARB1表达降低,二者均与肿瘤TNM分期、病理分级有关,可作为判断胃癌预后的肿瘤标志物。
基金supported by a grant from the National Natural Science Foundation of China(491010-N11026)
文摘BACKGROUND:Non-alcoholic fatty liver disease(NAFLD)is one of the most frequent causes of liver diseases,with markedly increased prevalence.However,its mechanisms are not clear.The present study was undertaken to illustrate the role of caveolin-1(cav1)and the scavenger receptor class B type 1(SR-B1)in NAFLD.METHODS:Adult male C57BL/6 mice were fed with a normal diet or high fat and cholesterol(HFC)diet for 14 weeks.The mice were sacrificed to collect plasma and harvest the liver;their plasma lipid concentration was measured.Hepatic cav1and SR-B1 mRNA and protein expression were determined by real-time quantitative polymerase chain reaction(qPCR)and Western blotting,respectively.In order to study cav1 and SR-B1distribution and change in hepatocytes,immunohistochemical analysis was performed.RESULTS:HFC diet increased plasma lipids,induced NAFLD and increased the liver/body weight ratio.Compared to the control mice(n=6),the mRNA and protein levels of cav1 and SR-B1 in liver tissue of the NAFLD mice(n=12)increased significantly(cav1 mRNA:1.536±0.226 vs 0.980±0.272,P【0.05;protein:0.643±0.240 vs 0.100±0.130,P【0.01;SR-B1 mRNA:1.377±0.125 vs 0.956±0.151,P【0.01;protein:2.156±0.507vs 0.211±0.211,P【0.01).Furthermore,both cav1 and SR-B1immunoreactivity increased and their distribution was also changed,mainly in the plasma membrane of hepatocytes,cytoplasm and membrane of lipid droplets and around.CONCLUSION:NAFLD is associated with increased concentration of plasma lipids and upregulation of hepatic cav1 and SR-B1 gene and protein expressions,which indicate that cav1 and SR-B1 might play crucial roles in the pathogenesis of NAFLD.
文摘Type 2 diabetes mellitus is a metabolic disorder of deranged fat, protein and carbohydrate metabolism resulting in hyperglycemia as a result of insulin resistance and inadequate insulin secretion. Although a wide variety of diabetes therapies is available, yet limited efficacy, adverse effects, cost, contraindications, renal dosage adjustments, inflexible dosing schedules and weight gain significantly limit their use. In addition, many patients in the United States fail to meet the therapeutic HbA1c goal of < 7% set by the American Diabetes Association. As such new and emerging diabetes therapies with different mechanisms of action hope to address some of these drawbacks to improve the patient with type 2 diabetes. This article reviews new and emerging classes, including the sodium-glucosecotransporter-2 inhibitors, 11β-Hydroxysteroid dehydrogenase type 1 inhibitors, glycogen phosphorylase inhibitors; protein tyrosine phosphatase 1B inhibitors, G Protein-Coupled receptor agonists and glucokinase activators. These emerging diabetes agents hold the promise of providing benefit of glucose lowering, weight reduction, low hypoglycemia risk, improve insulin sensitivity, pancreatic β cell preservation, and oral formulation availability. However, further studies are needed to evaluate their safety profile, cardiovascular effects, and efficacy durability in order to determine their role in type 2 diabetes management.
